{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:10:04Z","timestamp":1772147404605,"version":"3.50.1"},"reference-count":195,"publisher":"Elsevier","isbn-type":[{"value":"9780444642608","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.pbr.2019.10.007","type":"book-chapter","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T06:38:13Z","timestamp":1575268693000},"page":"451-492","source":"Crossref","is-referenced-by-count":12,"title":["Novel approaches to counter protein aggregation pathology in Parkinson's disease"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pbr.2019.10.007_bb0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0015","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces \u03b1-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0020","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1212\/WNL.44.8.1511","article-title":"Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease","volume":"44","author":"Alexander","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0025","doi-asserted-by":"crossref","first-page":"E4688","DOI":"10.1073\/pnas.1523597113","article-title":"Deubiquitinase Usp8 regulates \u03b1-synuclein clearance and modifies its toxicity in Lewy body disease","volume":"113","author":"Alexopoulou","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0006-8993(99)01848-X","article-title":"Cellular co-localization of phosphorylated tau- and NACP\/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies","volume":"843","author":"Arima","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0035","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0045","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0050","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2015","journal-title":"J. Park. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080705","article-title":"Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs","volume":"8","author":"Baptista","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0060","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1128\/JVI.02949-15","article-title":"Alpha-synuclein expression restricts RNA viral infections in the brain","volume":"90","author":"Beatman","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/07853890.2013.849003","article-title":"Glucocerebrosidase mutations and the pathogenesis of Parkinson disease","volume":"45","author":"Beavan","year":"2013","journal-title":"Ann. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2018.109","article-title":"Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing","volume":"17","author":"Boland","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0075","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.bbagen.2008.12.001","article-title":"Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases","volume":"1790","author":"Cahill","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12017-017-8447-9","article-title":"Deferiprone rescues behavioral deficits induced by mild iron exposure in a mouse model of alpha-synuclein aggregation","volume":"19","author":"Carboni","year":"2017","journal-title":"Neuromolecular Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson's disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"npj Park. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0095","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10072-012-1284-6","article-title":"Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease","volume":"34","author":"Chen","year":"2013","journal-title":"Neurol. Sci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0100","article-title":"Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055375","article-title":"Triggering of inflammasome by aggregated \u03b1-synuclein, an inflammatory response in synucleinopathies","volume":"8","author":"Codolo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/clpt.2013.10","article-title":"Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer","volume":"93","author":"Colca","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4939-9124-2_4","article-title":"Detection of misfolded \u03b1-synuclein aggregates in cerebrospinal fluid by the protein misfolding cyclic amplification platform","volume":"1948","author":"Concha-Marambio","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0120","first-page":"217","article-title":"Genetic neuropathology of Parkinson's disease","volume":"1","author":"Cookson","year":"2008","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2017.05.019","article-title":"A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses \u03b1-syn- and MPTP-induced toxicities in vivo","volume":"123","author":"Das","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/900a5247-7d03-4686-a544-5f7f64c0aac5","article-title":"Alpha-synuclein is a cellular ferrireductase","volume":"6","author":"Davies","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/ars.2015.6343","article-title":"Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease","volume":"24","author":"Deas","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/cdd.2016.104","article-title":"Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation","volume":"24","author":"Delgado-Camprubi","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0145","first-page":"1074","article-title":"Incidental Lewy body disease and preclinical Parkinson disease","volume":"65","author":"Delle Donne","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5429","article-title":"LRRK2 activation in idiopathic Parkinson's disease","volume":"10","author":"Di Maio","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0155","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-019-0336-2","article-title":"Glucocerebrosidase and its relevance to Parkinson disease","volume":"14","author":"Do","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic\u2014a call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0175","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1523\/JNEUROSCI.1560-11.2011","article-title":"Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of \u03b1-synuclein","volume":"31","author":"Ebrahimi-Fakhari","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0180","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1021\/acs.biochem.6b00149","article-title":"Structural effects of two camelid nanobodies directed to distinct C-terminal epitopes on \u03b1-synuclein","volume":"55","author":"El-Turk","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0185","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1021\/bi036281f","article-title":"Inhibiting aggregation of \u03b1-synuclein with human single chain antibody fragments","volume":"43","author":"Emadi","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","article-title":"Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases","volume":"92","author":"Espay","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0195","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12974-017-1036-x","article-title":"Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia","volume":"14","author":"Fan","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0200","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","article-title":"Lipidomic analysis of \u03b1-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment","volume":"73","author":"Fanning","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fnins.2016.00099","article-title":"Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy","volume":"10","author":"Fellner","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acschemneuro.5b00253","article-title":"Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice","volume":"7","author":"Finkelstein","year":"2016","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","article-title":"The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease","volume":"5","author":"Finkelstein","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-018-0497-5","article-title":"Activating autophagy as a therapeutic strategy for Parkinson's disease","volume":"32","author":"Fowler","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0225","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","article-title":"Antibody therapies in CNS diseases","volume":"120","author":"Freskg\u00e5rd","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0230","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neurobiolaging.2009.05.019","article-title":"Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies?","volume":"32","author":"Frigerio","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0235","doi-asserted-by":"crossref","first-page":"10392","DOI":"10.1074\/jbc.RA119.007743","article-title":"Defining \u03b1-synuclein species responsible for Parkinson's disease phenotypes in mice","volume":"294","author":"Froula","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0240","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","article-title":"Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication","volume":"68","author":"Fuchs","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3634","article-title":"Effect of selective LRRK2 kinase inhibition on nonhuman primate lung","volume":"7","author":"Fuji","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0250","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an \u03b1-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated \u03b1-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0255","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0260","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/brain\/awl114","article-title":"PINK1 protein in normal human brain and Parkinson's disease","volume":"129","author":"Gandhi","year":"2006","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0265","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1385\/NMM:5:3:235","article-title":"Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity","volume":"5","author":"Gardian","year":"2004","journal-title":"Neuromolecular Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0270","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0275","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neulet.2013.12.028","article-title":"Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human \u03b1-synuclein: feasibility study","volume":"560","author":"Ghochikyan","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2210","article-title":"Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinsons disease","volume":"8","author":"Ghosh","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0290","doi-asserted-by":"crossref","first-page":"E2634","DOI":"10.1073\/pnas.1713849115","article-title":"Identification of a highly neurotoxic \u03b1-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease","volume":"115","author":"Grassi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0295","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson's disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0305","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/mds.20752","article-title":"Association of \u03b1-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset","volume":"21","author":"Hadjigeorgiou","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0310","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neurobiolaging.2018.02.028","article-title":"Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain","volume":"67","author":"Hallett","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0315","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr\u2013Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0325","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0330","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0335","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0140-6736(92)90313-R","article-title":"\u201cWearing-off\u201d and beta 2-adrenoceptor agonist in Parkinson's disease","volume":"339","author":"Hishida","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0340","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/cbf.3364","article-title":"LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase","volume":"36","author":"Ho","year":"2018","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12915-017-0390-6","article-title":"Nanobodies raised against monomeric \u0251-synuclein inhibit fibril formation and destabilize toxic oligomeric species","volume":"15","author":"Iljina","year":"2017","journal-title":"BMC Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0350","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/j.1471-4159.2006.04440.x","article-title":"Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone","volume":"101","author":"Inden","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0355","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","article-title":"Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"377","author":"International Parkinson Disease Genomics Consortium","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0360","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0365","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat8407","article-title":"Poly(ADP-ribose) drives pathologic \u03b1-synuclein neurodegeneration in Parkinson's disease","volume":"362","author":"Kam","year":"2018","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0370","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0375","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0380","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1038\/cddis.2013.447","article-title":"(ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease","volume":"4","author":"Kim","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0385","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1073\/pnas.1700465115","article-title":"GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0390","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body\u2013like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0395","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40261-019-00771-y","article-title":"Chronic use of \u03b2-blockers and the risk of Parkinson's disease","volume":"39","author":"Koren","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0400","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.jmb.2014.04.015","article-title":"A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies","volume":"426","author":"Krishnan","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0405","first-page":"1","article-title":"Translational inhibition of \u03b1-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice","volume":"8","author":"Kuo","year":"2019","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0410","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.106.112102","article-title":"The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-\u03b2 peptide levels in cell culture and mice","volume":"320","author":"Lahiri","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-016-8417-7","article-title":"mTOR signaling in Parkinson's disease","volume":"19","author":"Lan","year":"2017","journal-title":"Neuromolecular Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0420","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","article-title":"Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease","volume":"16","author":"Lee","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0425","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/nn.3500","article-title":"Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss","volume":"16","author":"Lee","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0430","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","article-title":"The c-Abl inhibitor, radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model","volume":"27","author":"Lee","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0435","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","article-title":"MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration","volume":"26","author":"Lee","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0440","first-page":"141","article-title":"NPT088 reduces both amyloid-\u03b2 and tau pathologies in transgenic mice","volume":"2","author":"Levenson","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0445","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","article-title":"The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset","volume":"127","author":"Levin","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0450","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0455","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0460","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1073\/pnas.1605245113","article-title":"Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054887","article-title":"Neurotrophic and neuroprotective actions of (\u2212)- and (+)-phenserine, candidate drugs for Alzheimer's disease","volume":"8","author":"Lilja","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0475","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jmb.2007.11.096","article-title":"An scFv intrabody against the nonamyloid component of \u03b1-synuclein reduces intracellular aggregation and toxicity","volume":"377","author":"Lynch","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0480","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","article-title":"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-\u03b2 peptide and \u03c4 levels: target engagement, tolerability and pharmacokinetics in humans","volume":"83","author":"Maccecchini","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0485","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0490","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"c-Abl phosphorylates \u03b1-synuclein and regulates its degradation: implication for \u03b1-synuclein clearance and contribution to the pathogenesis of Parkinson's disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0495","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1073\/pnas.96.10.5774","article-title":"Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism","volume":"96","author":"Mandir","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0500","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1471-4159.2002.01144.x","article-title":"A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism","volume":"83","author":"Mandir","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0505","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0510","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0515","series-title":"Advances in Neurobiology","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-319-49969-7_5","article-title":"LRRK2 and autophagy","author":"Manzoni","year":"2017"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0520","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.bbamcr.2013.07.020","article-title":"Inhibition of LRRK2 kinase activity stimulates macroautophagy","volume":"1833","author":"Manzoni","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0525","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1750-1172-8-140","article-title":"Unfolded protein response in Gaucher disease: from human to Drosophila","volume":"8","author":"Maor","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0530","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","volume":"25","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0535","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/NEN.0b013e3181ac10a7","article-title":"Lewy body pathology in normal elderly subjects","volume":"68","author":"Markesbery","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0540","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.009","article-title":"Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2\/neu overexpression","volume":"449","author":"M\u00e1rquez-Garb\u00e1n","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0545","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of \u03b1-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0555","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0560","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0565","first-page":"31","article-title":"A proposed roadmap for Parkinson's disease proof of concept clinical trials investigating compounds targeting alpha-synuclein","volume":"9","author":"Merchant","year":"2019","journal-title":"J. Park. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0570","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0575","doi-asserted-by":"crossref","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/142372","article-title":"The anticholinesterase phenserine and its enantiomer posiphen as 5\u2032 untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression","volume":"2012","author":"Mikkilineni","year":"2012","journal-title":"Parkinsons Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0585","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/hmg\/ddh131","article-title":"Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy","volume":"13","author":"Minamiyama","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0590","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0595","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.tins.2018.11.001","article-title":"Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson's disease","volume":"42","author":"Nguyen","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0600","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF00571500","article-title":"Cu\/Zn superoxide dismutase-like immunoreactivity is present in Lewy bodies from Parkinson disease: a light and electron microscopic immunocytochemical study","volume":"89","author":"Nishiyama","year":"1995","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0605","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1021\/acs.biochem.8b00579","article-title":"Small molecule modulation of proteasome assembly","volume":"57","author":"Njomen","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0610","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/biom7030052","article-title":"Regulation of autophagy through TORC1 and mTORC1","volume":"7","author":"Noda","year":"2017","journal-title":"Biomolecules"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0615","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.parkreldis.2009.03.002","article-title":"A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human \u03b1-synuclein A30P+A53T transgenic mice","volume":"15","author":"Ono","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0620","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","article-title":"The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity","volume":"20","author":"Ostrerova-Golts","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0625","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fneur.2018.00415","article-title":"Are we ready for detecting \u03b1-synuclein prone to aggregation in patients? The case of \u201cprotein-misfolding cyclic amplification\u201d and \u201creal-time quaking-induced conversion\u201d as Diagnostic Tools","volume":"9","author":"Paciotti","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0630","first-page":"503","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Park. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0640","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure\u2013activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0645","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fmolb.2019.00016","article-title":"Novel mannitol-based small molecules for inhibiting aggregation of \u03b1-synuclein amyloids in Parkinson's disease","volume":"6","author":"Paul","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0650","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0655","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep inhibition of \u03b1-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0660","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/j.1471-4159.1992.tb10074.x","article-title":"Detergent-insoluble cortical lewy body fibrils share epitopes with neurofilament and tau","volume":"58","author":"Pollanen","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0665","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0670","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0675","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.4049\/jimmunol.1002449","article-title":"\u03b22-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway","volume":"186","author":"Qian","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0680","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12974-018-1236-z","article-title":"Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP\/p mouse model of Parkinson's disease","volume":"15","author":"Qiao","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0685","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-018-0260-x","article-title":"Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration","volume":"13","author":"Quansah","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0695","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0700","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents \u03b1-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0705","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00702-010-0513-5","article-title":"The alpha-synuclein 5\u2032untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen","volume":"118","author":"Rogers","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0710","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1474-4422(11)70175-2","article-title":"Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case\u2013control study","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0715","doi-asserted-by":"crossref","first-page":"18666","DOI":"10.1073\/pnas.1105725108","article-title":"\u03b1-synuclein fate is determined by USP9X-regulated monoubiquitination","volume":"108","author":"Rott","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038113","article-title":"Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease","volume":"7","author":"Roy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0725","doi-asserted-by":"crossref","first-page":"e1368","DOI":"10.1038\/cddis.2014.320","article-title":"The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling","volume":"5","author":"Saez-Atienzar","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0730","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0735","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/NEN.0b013e31829768d2","article-title":"\u03b1-synuclein vaccination prevents the accumulation of Parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model","volume":"72","author":"Sanchez-Guajardo","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0740","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects \u03b1-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0745","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0750","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"Sardi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0755","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0760","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nbd.2017.12.005","article-title":"Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble \u03b1-synuclein in neurons","volume":"111","author":"Schapansky","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0765","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0770","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0002-9440(10)61113-3","article-title":"Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies","volume":"160","author":"Schlossmacher","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0775","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26377","article-title":"Active immunization therapies for Parkinson's disease and multiple system atrophy","volume":"31","author":"Schneeberger","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0785","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"\u03b22-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0790","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1074\/jbc.M112.434787","article-title":"A blood-brain barrier (BBB) disrupter is also a potent \u03b1-synuclein (\u03b1-syn) aggregation inhibitor","volume":"288","author":"Shaltiel-Karyo","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0795","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.1073\/pnas.131152998","article-title":"Phenserine regulates translation of -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development","volume":"98","author":"Shaw","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0800","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0805","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0810","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1074\/jbc.M208641200","article-title":"Aggregated and monomeric \u03b1-synuclein bind to the S6\u2032 proteasomal protein and inhibit proteasomal function","volume":"278","author":"Snyder","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0815","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0820","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"\u03b1-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0825","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00441-018-2814-1","article-title":"The concept of alpha-synuclein as a prion-like protein: ten years after","volume":"373","author":"Steiner","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0830","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s13311-016-0447-1","article-title":"Neuroprotection by epigenetic modulation in a transgenic model of multiple system atrophy","volume":"13","author":"Sturm","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0835","first-page":"37","article-title":"Translational inhibition of APP by Posiphen: efficacy, pharmacodynamics, and pharmacokinetics in the APP\/PS1 mouse","volume":"4","author":"Teich","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0840","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00401-017-1726-6","article-title":"Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain","volume":"134","author":"Trist","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0845","series-title":"Molecular Biology of Neurodegenerative Diseases: Visions for the Future","first-page":"1","article-title":"Can infections trigger alpha-synucleinopathies?","author":"Tulisiak","year":"2019"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0850","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00002826-200307000-00011","article-title":"Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease","volume":"26","author":"Uc","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0855","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1012033","article-title":"Evaluation of an \u03b1 synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease","volume":"11","author":"Ugen","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0860","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1196\/annals.1332.003","article-title":"The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5\u2032-untranslated region","volume":"1035","author":"Venti","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0865","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.celrep.2018.11.028","article-title":"Inhibiting stearoyl-CoA desaturase ameliorates \u03b1-synuclein cytotoxicity","volume":"25","author":"Vincent","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0870","series-title":"Handbook of Clinical Neurology","first-page":"321","article-title":"Prion-like propagation of pathology in Parkinson disease","author":"Volpicelli-Daley","year":"2018"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0875","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1523\/JNEUROSCI.3642-15.2016","article-title":"G2019S-LRRK2 expression augments-synuclein sequestration into inclusions in neurons","volume":"36","author":"Volpicelli-Daley","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0880","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0885","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","article-title":"The Lewy body in Parkinson's disease and related neurodegenerative disorders","volume":"47","author":"Wakabayashi","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0890","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh\u00ae amyloid-\u03b2 vaccine for immunotherapy of Alzheimer's disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0895","first-page":"262","article-title":"UB-311, a novel UBITh \u00ae amyloid \u03b2 peptide vaccine for mild Alzheimer's disease","volume":"3","author":"Wang","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0900","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000478741","article-title":"Lessons from anti-amyloid-\u03b2 immunotherapies in Alzheimer disease: aiming at a moving target","volume":"17","author":"Wang","year":"2017","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0905","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0910","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0915","doi-asserted-by":"crossref","first-page":"e8931","DOI":"10.15252\/emmm.201808931","article-title":"Enriched environment enhances \u03b2-adrenergic signaling to prevent microglia inflammation by amyloid-\u03b2","volume":"10","author":"Xu","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0920","doi-asserted-by":"crossref","first-page":"12580","DOI":"10.1074\/jbc.M511677200","article-title":"Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA","volume":"281","author":"Ying","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0925","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/jnr.22310","article-title":"Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice","volume":"88","author":"Yokoyama","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0930","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1871523011312020003","volume":"12","author":"Yu","year":"2013","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0935","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fphar.2019.00016","article-title":"Canthin-6-one accelerates alpha-synuclein degradation by enhancing UPS activity: drug target identification by CRISPR-Cas 9 whole genome-wide screening technology","volume":"10","author":"Yuan","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0940","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0945","doi-asserted-by":"crossref","first-page":"15978","DOI":"10.1073\/pnas.1108558108","article-title":"Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential","volume":"108","author":"Zasloff","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0950","first-page":"157","article-title":"Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson's disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Park. Dis."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0955","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson's disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0960","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2004.08.019","article-title":"A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed \u03b1-synuclein","volume":"10","author":"Zhou","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0965","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate Up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0970","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-019-00759-8","article-title":"Tetramethylpyrazine analogue T-006 promotes the clearance of alpha-synuclein by enhancing proteasome activity in Parkinson's disease models","author":"Zhou","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pbr.2019.10.007_bb0975","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.20928","article-title":"LRRK2 protein is a component of Lewy bodies","volume":"60","author":"Zhu","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.pbr.2019.10.007_bb0980","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","article-title":"Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide","volume":"97","author":"Zunke","year":"2018","journal-title":"Neuron"}],"container-title":["Progress in Brain Research","Recent Advances in Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612319302043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612319302043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:06:50Z","timestamp":1758751610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612319302043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780444642608"],"references-count":195,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2019.10.007","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}